Aluminium hydroxide adsorption and factor VIII clotting assays

Antibodies against TFPI and protein C are associated with a severe thrombotic phenotype in patients with and without antiphospholipid syndrome.

Thrombosis research·2018

A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem™ PT).

International journal of laboratory hematology·2017

Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2016

Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.

Journal of thrombosis and haemostasis : JTH·2015

Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.

Thrombosis research·2015

Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.

Journal of thrombosis and haemostasis : JTH·2014

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Thermal Switching of Electron Transfer at a VO_{2} Heterointerface for Accelerated Oxygen Evolution.

Physical review letters·2026

Experimental Realization of Thermal Reservoirs with Tunable Temperature in a Trapped-Ion Spin-Boson Simulator.

Physical review letters·2026

Diffusion in Two-Dimensional Hyperuniform Media.

Physical review letters·2026

An injectable thermosensitive HTCC/Pluronic F127 hydrogel with sustained EGF release for accelerated diabetic wound healing.

Biomaterials science·2026

Hybrid Dynamic-Covalent PEG Hydrogels With Enhanced Stability for Photothermally Triggered Pulsatile Drug Delivery.

Macromolecular bioscience·2026

Characterization of Breeding Success and Litter Characteristics in the New Mexico Alcohol Research Center Moderate Drinking Paradigm.

Alcohol (Fayetteville, N.Y.)·2026

Related Experiment Videos

Aluminium hydroxide adsorption and factor VIII clotting assays

Related Concept Videos

Antibodies against TFPI and protein C are associated with a severe thrombotic phenotype in patients with and without antiphospholipid syndrome.

A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem™ PT).

Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.

Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.

Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.

Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Thermal Switching of Electron Transfer at a VO_{2} Heterointerface for Accelerated Oxygen Evolution.

Experimental Realization of Thermal Reservoirs with Tunable Temperature in a Trapped-Ion Spin-Boson Simulator.

Diffusion in Two-Dimensional Hyperuniform Media.

An injectable thermosensitive HTCC/Pluronic F127 hydrogel with sustained EGF release for accelerated diabetic wound healing.

Hybrid Dynamic-Covalent PEG Hydrogels With Enhanced Stability for Photothermally Triggered Pulsatile Drug Delivery.

Characterization of Breeding Success and Litter Characteristics in the New Mexico Alcohol Research Center Moderate Drinking Paradigm.

Related Experiment Videos

Aluminium hydroxide adsorption and factor VIII clotting assays

Related Concept Videos

Related Articles